CORAL GABLES, Fla., Aug. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the second quarter ended June 30, 2023. The Company will host a conference call today, Tuesday, August 8, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
Read more at prnewswire.comRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here